Genmab — Februar 2023
-
Godmorgen.
-
Jeg er enig Stockbull. TA fylder meget lidt i chats og debat her på sitet i. Det uagtet at interessen er meget stor. Dine TA tråde i debatten og dem fra TheNote har rigtig mange læsere. Det samme med de langsigtede trendanalyser fra Rida vi havde fornøjelsen af i en periode. Han starter snart op igen på Proinvestor.
-
Rida´s TA analyser har vi liggende her. De bliver opdateret i den kommende tid:
https://www.proinvestor.com/analyser -
Jeg glemte selvfølgelig at nævne Nordicstock og Hans-Henrik Nielsen. Sidsnævnte har for øjeblikket travlt med sin TA-baseret fond. Derfor er der langt mellem hans videoer i debatten for øjeblikket.
-
Stoxx: Til gengæld lægger europæisk health care op til et teknisk brud opad
Kursgraf: Med stigende renter kan sektor-rotationen ud af tech over i defensiv healthcare blive accelereret.
Økonomisk Ugebrev (ugebrev.dk)
-
Dagens aktie er Genmab $GENMAB - international bioteknologisk virksomhed med speciale i antistofterapi til behandling af kræft.
4 stk. proprietære teknologier DuoBody, HexaBody, DuoHexaBody og HexElect
1.560 ansatte
Kommer med årsrapport d. 22 februar 2023.
Go big or go home https://twitter.com/dagensaktiedk/status/1623692890835677185 -
AbbVie (ABBV) Q4 2022 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2023/02/09/abbvie-abbv-q4-2022-earnings-call-transcript/#:~:text=We delivered full year 2022,of combined sales in 2022.
-
We also anticipate regulatory approvals this year for epcoritamab in relapsed refractory large B-cell lymphoma in several major geographies, including the U.S. in the second quarter and in Europe and Japan in the second half of the year.
Based on the very deep and durable responses demonstrated thus far in our clinical program, we believe that epcoritamab has the potential to significantly improve upon treatment options for these patients.
-
We believe that epcoritamab has the potential to become a core therapy for B-cell malignancies. And we continue to make very good progress expanding our development programs for epcoritamab across several indications. Over the course of 2023, we expect to begin several new studies, including a phase 3 study in front-line DLBCL in combination with R-CHOP and multiple phase 2 studies in CLL and MCL.
-
Der blev lidt stille! Men det er ds godt nok også et voldsomt pres på idag…:-(
-
Nyder stilheden og roen
Helge har sikkert en anden opfattelse af den manglende trafik herinde. Solgte i øvrigt en pæn bid i går og genkøbt i dag. -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind